Oncology

Latest News

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

May 6th 2025

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com
COA 2025: Insight, Innovation, and Independent Strength

May 5th 2025

COA logo | Image Credit: © Amy Kinnamon
Community Oncology Reacts to Trump's Drug Pricing Executive Order

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com
5 Things You Should Know About Skin Cancer

May 2nd 2025

stethoscopewithcompass | Image Credit: © Talaj-stock.adobe.com
Patient Navigation Is Nonnegotiable in Cancer Care

May 1st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
December 10th 2017

Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care

Surabhi Dangi-Garimella, PhD
During a session on the first day of the 59th Annual Meeting and Exposition of the American Society of Hematology in Atlanta, Georgia, physicians shared current knowledge on cardiovascular toxicities of tyrosine kinase inhibitors (TKIs) as well as the potential for treatment-free remission with these agents.
UC San Diego Researchers Receive $600,000 Grant to Test PI3Ky Inhibitor
December 9th 2017

UC San Diego Researchers Receive $600,000 Grant to Test PI3Ky Inhibitor

Kelly Davio
A University of California San Diego School of Medicine and Moores Cancer Center research team studying new drugs that could break resistance to cancer immunotherapy has received a 3-year, $600,000 translational grant from the V Foundation for Cancer Research.
This Week in Managed Care: December 8, 2017
December 8th 2017

This Week in Managed Care: December 8, 2017

This week, the top managed care stories included CVS' proposal to purchase Aetna, which could reshape healthcare; a new study that looks at who is dying in hospitals from opioid use; and CMS reported that healthcare spending grew more slowly in 2016.
Ribociclib Plus Oral Endocrine Partner Shows Efficacy in Women With HR+/HER2- Breast Cancer
December 8th 2017

Ribociclib Plus Oral Endocrine Partner Shows Efficacy in Women With HR+/HER2- Breast Cancer

Jaime Rosenberg
Novartis announced that Phase III MONALEESA-7 trial results showed that the combination of ribociclib with an endocrine therapy (tamoxifen or an aromatase inhibitor) and goserelin yielded significant progression-free survival when compared with endocrine therapy and goserelin alone.
How Physicians Handle Differing Guidelines on Breast Cancer Screening Recommendations
December 6th 2017

How Physicians Handle Differing Guidelines on Breast Cancer Screening Recommendations

Laura Joszt, MA
WIth different societies and organizations releasing contrary guidelines around breast cancer screening, experience with past patients or friends and family members could influence physicians' decisions around when to start screening mammography.
Site Logo
December 6th 2017

Having Cancer Saved My Life

Samantha Eisenstein Watson, MBA
A Samfund grant recipient narrates her experience of being diagnosed young with cancer and how the support from The Samfund "made everyday school and life manageable."
Scientists Discover Gene That May Cause Melanoma to Metastasize
December 6th 2017

Scientists Discover Gene That May Cause Melanoma to Metastasize

Samantha DiGrande
A new study published Monday by scientists at the University of Massachusetts Medical School (UMMS) in Boston reports findings on a gene that is responsible for creating a protein that may help melanoma to grow and metastasize.
Systematic Review Finds Elevated Reporting for Thromboembolic Events With JAK Inhibitors
December 5th 2017

Systematic Review Finds Elevated Reporting for Thromboembolic Events With JAK Inhibitors

Kelly Davio
A systematic review of the FDA’s Adverse Event Reporting System (FAERS) found elevated reporting for both tofacitinib (Xeljanz) and ruxolitinib (Jakafi) for thromboembolic adverse events (AEs), suggesting the possibility of a class-wide issue with Janus kinase (JAK) inhibitors.
Site Logo
December 5th 2017

Majority of Patients Go Online for Information Following Cancer Diagnosis, Study Finds

Jaime Rosenberg
Health information brand Healthline launched its “State of…” series with its “State of Cancer” study, analyzing how digital information influences patient treatment decisions and recognizing generational differences.
First-of-a-Kind Companion Test for Cancer Gene Profiling Gets FDA Approval
December 5th 2017

First-of-a-Kind Companion Test for Cancer Gene Profiling Gets FDA Approval

Jaime Rosenberg
The FDA has approved Foundation Medicine's FoundationOne CDx, the first-of-a-kind comprehensive companion diagnostic test for solid tumors. The test looks for hundreds of cancer genes, providing healthcare professionals with a more complete picture of what's causing tumor growth and guidance for treatment decisions.
Site Logo
December 5th 2017

Study Compares Survival for Cancer, Based on Health Insurance Status

Samantha DiGrande
A study published Thursday in JAMA Oncology found that improvements in survival among California cancer patients were almost exclusively limited to patients with private or Medicare insurance.
Site Logo
December 1st 2017

The Importance of Teamwork in Oncology Care Transitions

Surabhi Dangi-Garimella, PhD
A panel on the importance of clinical and non-clinical stakeholders in a patient’s care trajectory brought together a diverse group of stakeholders at The American Journal of Managed Care®’s Patient-Centered Oncology Care® meeting.
Diabetes, High BMI Account for Nearly 800,000 New Cancer Cases Worldwide
November 30th 2017

Diabetes, High BMI Account for Nearly 800,000 New Cancer Cases Worldwide

Mary Caffrey
Liver and endometrial cancer accounted for high numbers of new cases; increases of these cancer types have been attributed to rising rates of diabetes and obesity.
Shawnee Mission Health Partners With Top-Ranked Cancer Network to Deliver World-Class Cancer Care Locally
November 30th 2017

Shawnee Mission Health Partners With Top-Ranked Cancer Network to Deliver World-Class Cancer Care Locally

Jaime Rosenberg
After a year-long process, Shawnee Mission Health (SMH) is now a certified member of the MD Anderson Cancer Network, the top ranked cancer center in the US. The 2 will work together to raise the standard of cancer care in the Kansas City metropolitan community through patient-centered care.
Site Logo
November 30th 2017

African Americans Are More Likely to Have MM, but Are Underrepresented in Research

Kelly Davio
While African Americans are 3 times more likely than Caucasians to be diagnosed with multiple myeloma (MM)—and twice as likely to die of the disease—they are underrepresented in MM disease research.
Site Logo
November 28th 2017

Significant Amount of Cancer Cases Attributable to Potentially Modifiable Risk Factors

Jaime Rosenberg
A study published in CA: A Cancer Journal for Clinicians found that 42% of all incident cancer cases in US adults age 30 years or older in 2014 were attributable to potentially modifiable exposures. Exposures included smoking, alcohol intake, physical inactivity, and low fiber intake.
Ovarian Cancer: Coverage of PARP Inhibitors
November 28th 2017

Ovarian Cancer: Coverage of PARP Inhibitors

Consulting With Gynecologic Oncologists for Input
November 28th 2017

Consulting With Gynecologic Oncologists for Input

Guidance for Payer Decisions in Ovarian Cancer
November 28th 2017

Guidance for Payer Decisions in Ovarian Cancer

Management Challenges in Ovarian Cancer
November 28th 2017

Management Challenges in Ovarian Cancer

Patient Selection and PARP Inhibitors in Ovarian Cancer
November 28th 2017

Patient Selection and PARP Inhibitors in Ovarian Cancer

Predictive Markers in Ovarian Cancer
November 28th 2017

Predictive Markers in Ovarian Cancer

Ovarian Cancer: Practical Considerations in Maintenance
November 28th 2017

Ovarian Cancer: Practical Considerations in Maintenance

Efficacy and Safety of Rucaparib: A Focus on ARIEL3
November 28th 2017

Efficacy and Safety of Rucaparib: A Focus on ARIEL3

Efficacy and Safety of Olaparib and Niraparib in Switch Maintenance
November 28th 2017

Efficacy and Safety of Olaparib and Niraparib in Switch Maintenance

Delaying Recurrence in Ovarian Cancer
November 28th 2017

Delaying Recurrence in Ovarian Cancer

Role of PARP Inhibition in Ovarian Cancer
November 28th 2017

Role of PARP Inhibition in Ovarian Cancer

Expertise on the Ovarian Cancer Healthcare Team
November 28th 2017

Expertise on the Ovarian Cancer Healthcare Team

Understanding Ovarian Cancer
November 28th 2017

Understanding Ovarian Cancer

Substantial Proportion of Patients Diagnosed With Incident Cancer Have Survived a Prior Cancer
November 28th 2017

Substantial Proportion of Patients Diagnosed With Incident Cancer Have Survived a Prior Cancer

Jaime Rosenberg
A study published in JAMA Oncology found that a significant number of patients newly diagnosed with cancer have had a prior cancer. The prevalence differed among age group and incident cancer type.
<1
...
606162636465666768
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo